Premium
The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study
Author(s) -
Fleming K. M.,
Aithal G. P.,
Card T. R.,
West J.
Publication year - 2010
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2010.04473.x
Subject(s) - decompensation , cirrhosis , medicine , disease , cohort , population , mortality rate , liver disease , alcoholic liver disease , clinical practice , intensive care medicine , gastroenterology , physical therapy , environmental health
Aliment Pharmacol Ther 2010; 32: 1343–1350 Summary Background We lack population‐based estimates of the rate of decompensation in people with compensated cirrhosis as well as estimates of the manner in which the disease progresses once identified. Aim To determine the rate of decompensation and clinical progression of disease in patients with cirrhosis based upon clinical symptoms recorded electronically in general practice data. Methods Using Cox proportional hazards regression, we modelled the rate of decompensation for patients from the UK General Practice Research Database with a diagnosis of cirrhosis between 1987 and 2002. We determined the clinical progression in the first year following diagnosis and subsequently categorizing patients through time according to a simple clinical staging system agreed at the Baveno IV consensus conference. Results The rate of decompensation in patients with compensated cirrhosis was found to be 11% overall. The rate of decompensation was higher in the first year (at 31% compared with 7.3% afterwards) and in patients with an alcoholic aetiology. Patients with compensated cirrhosis had a 1‐year probability of proceeding directly to death of 7% compared with 20% in patients with decompensated cirrhosis. Conclusions Using data recorded in general practice records, it is possible to determine the rate of decompensation and the clinical progression of disease in people with cirrhosis.